Clinical Trials Logo

Filter by:
NCT ID: NCT04621851 Recruiting - Clinical trials for Chronic Myeloid Leukemia

Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation

Start date: September 30, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to investigate the safety profile of TKI discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.

NCT ID: NCT04621708 Recruiting - Multiple Sclerosis Clinical Trials

Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS

Start date: April 30, 2020
Phase: N/A
Study type: Interventional

The main purpose of this study is to investigate the safety and tolerability of intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms as well as its effects on cognition. Although iTBS rTMS is approved for use, there have been no safety and tolerability evaluations of this form of rTMS in Multiple Sclerosis (MS).

NCT ID: NCT04621396 Recruiting - Type 2 Diabetes Clinical Trials

The Next Generation Longitudinal Birth Cohort Diabetes Study

NextGen
Start date: September 2013
Phase:
Study type: Observational

The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.

NCT ID: NCT04620590 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Start date: April 20, 2021
Phase: Phase 4
Study type: Interventional

Open label, mechanistic, single-arm study to evaluate the natriuretic effect of 2 weeks dapagliflozin treatment in T2DM patients with impaired renal function. It will measure the average change in 24-hr sodium excretion from average Baseline to average values at Day 2 to 4 within the study group. The study will allow for an up to 6-week Screening and Run-in Period, a 2-week Treatment Period and a 5-day Follow-up Period. Patients will consume food from standardized food boxes starting on Day -6 (patients not on insulin) or Day -20 at the earliest (patients on insulin) of the study until Day 18 (inclusive). Eligible patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days starting on Day 1. This will be followed by a Follow-up Period of 5 days.

NCT ID: NCT04620226 Recruiting - Hepatitis C Clinical Trials

UHN Inpatient Hepatitis C & B Screening

Start date: February 1, 2024
Phase: Phase 4
Study type: Interventional

Currently, there is a lack of literature on programs evaluating rapid screening methods to traditional venipuncture methods for sample collection during screening for viral hepatitis. Due to the relatively low diagnosis and linkage to care rate, screening programs that provide same day results for viral hepatitis infection may improve both diagnosis and enable providers to engage patients shortly after diagnosis. This stands in contrast to the multi-visit, weeks long process that normally accompanies serum testing for hepatitis C virus (HCV) and hepatitis B virus (HBV). A few American studies have examined the implementation of HCV inpatient screening programs; however, they are focused specifically on high-risk patient populations, the barriers to accessing care experienced by study participants are not relevant to the Canadian healthcare system context, and do not use rapid testing. Furthermore, there are few, if any, data on HBV inpatient screening programs and the diagnosis rate remains low. This project will provide key data on a rapid inpatient screening and linkage to care strategy as well as the prevalence of these viruses across different age bands within the population. Finally, the study will help determine whether rapid inpatient screening is a feasible and acceptable approach for screening and linkage to care.

NCT ID: NCT04619862 Recruiting - Pain Clinical Trials

Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

Children born with severe brain-based developmental disabilities frequently experience persistent unexplained periods of pain and irritability, often compounded by a limited capacity to communicate their distress. The investigators call this entity Pain and Irritability of Unknown Origin (PIUO). The rationale of this trial is to identify the clinical effect size of gabapentin in reducing and resolving pain in children with developmental brain disorders, specifically those with severe neurological impairment (SNI).

NCT ID: NCT04619745 Recruiting - Clinical trials for Congenital Heart Defect

A Feasibility Study of Physical Activity After Surgical or Catheterization Intervention

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

This feasibility study will assess whether a 6-month, home-based, parent-led physical activity program, completed after surgical or catheterization treatment, enables young children with congenital heart defects (CHD) to achieve the recommended 180 minutes of daily physical activity. This study includes comprehensive measures of motor skill and physical activity, intervening at a very young age, and targeting the high risk status for sedentary lifestyles of children with CHD. This study will provide essential data on patient recruitment, data collection procedures, the proposed physical activity intervention and resources required to enable the design of a randomized controlled trial (RCT) to evaluate play-based, parent-delivered interventions optimized to support age-appropriate physical activity and motor skills among young children with CHD.

NCT ID: NCT04617327 Recruiting - Clinical trials for Soft Tissue Sarcoma Adult

Pre-operative RadiothErapy for Soft Tissue SarcOmas

PRESTO
Start date: June 5, 2020
Phase: N/A
Study type: Interventional

Soft tissue sarcomas (STSs) are malignant tumours that arise in any of the mesodermal tissues in the body including muscles, fibrous tissues, bone and cartilage, adipose tissue, and blood vessels, most frequently in the extremities (40%), trunk and retroperitoneum (40%). Traditionally, the prescription schedule for conventional preoperative RT is a regimen of 50 Gy in fractions of 1.8-2 Gy per day. Concerns regarding this regimen include the delay to definitive surgery and the higher rate of wound complications compared to post-operative radiotherapy. Hypofractionated RT is a prescription schedule in which the total dose of radiation is delivered in larger doses per fraction in fewer fractions allowing the delivery of a higher biologically effective dose (BED) to the tumour than with conventional RT [7] during a shorter period of time.

NCT ID: NCT04616482 Recruiting - Diet Modification Clinical Trials

Therapeutic Nutrition With Technology in Primary Care

Start date: September 15, 2020
Phase:
Study type: Observational

Low-carbohydrate diets (less than approximately 130 grams per day) are emerging as an efficacious treatment option with several studies supporting weight loss and remission of type 2 diabetes. Many physicians are now implementing this strategy but the time it takes to educate patients on nutrition is a barrier. The research team is working with physicians to develop a solution whereby the nutrition education and intervention is delivered via mobile/online technology (i.e., an app). This study will test whether it is feasible and efficacious for physicians to recommend this app to their patients with obesity and type 2 diabetes to help them lose weight and improve their condition.

NCT ID: NCT04616313 Recruiting - E Cigarette Use Clinical Trials

Novel Pulmonary Imaging of Lung Structure and Function in E-cigarette Smokers

Start date: January 17, 2023
Phase:
Study type: Observational

This is a longitudinal study of the long-term health impact of e-cigarette smoking on the lungs. Participants will be followed over a period of 5 years, and impacts of e-cigarette smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.